Article and Video CATEGORIES
Dr. Jenny Jing Li is originally from China. She earned her undergraduate degree from Duke University where she majored in neuroscience and biology. She received her M.D. degree from Duke University School of Medicine and completed her Internal Medicine residency at University of Texas Southwestern Medical Center. She is currently undergoing her hematology/oncology fellowship training at Mayo Clinic in Rochester, MN
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community.
In this video, Dr. Li discusses which patients with advanced NSCLC are good candidates for first line immunotherapy alone today.
******
李仁妮博士加入GRACE，担任客座教授，为普通话社区提供最新信息给我们的普通话肺癌视频库。 在此视频中，李医生讨论了哪些晚期NSCLC患者今天仅是一线免疫治疗的好人选。
To join the conversation, visit https://cancergrace.org/forum.
要加入对话，请访问https://cancergrace.org/forum。
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…